Annual CFF
$462.96 M
+$272.81 M+143.47%
31 December 2023
Summary:
Iovance Biotherapeutics annual cash flow from financing activities is currently $462.96 million, with the most recent change of +$272.81 million (+143.47%) on 31 December 2023. During the last 3 years, it has fallen by -$113.46 million (-19.68%). IOVA annual CFF is now -19.68% below its all-time high of $576.42 million, reached on 31 December 2020.IOVA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$41.95 M
-$110.87 M-72.55%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly cash flow from financing activities is currently $41.95 million, with the most recent change of -$110.87 million (-72.55%) on 30 September 2024. Over the past year, it has dropped by -$160.85 million (-79.31%). IOVA quarterly CFF is now -92.62% below its all-time high of $568.47 million, reached on 30 June 2020.IOVA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$389.32 M
-$160.85 M-29.24%
30 September 2024
Summary:
Iovance Biotherapeutics TTM cash flow from financing activities is currently $389.32 million, with the most recent change of -$160.85 million (-29.24%) on 30 September 2024. Over the past year, it has dropped by -$263.25 million (-40.34%). IOVA TTM CFF is now -40.34% below its all-time high of $652.57 million, reached on 30 September 2023.IOVA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +143.5% | -79.3% | -40.3% |
| 3 y3 years | -19.7% | +102.0% | +63.5% |
| 5 y5 years | +9.1% | +6218.4% | +60.0% |
IOVA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -19.7% | +143.5% | -83.8% | +2129.7% | -40.3% | >+9999.0% |
| 5 y | 5 years | -19.7% | +7451.1% | -92.6% | +2129.7% | -40.3% | >+9999.0% |
| alltime | all time | -19.7% | >+9999.0% | -92.6% | +2129.7% | -40.3% |
Iovance Biotherapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $41.95 M(-72.5%) | $389.32 M(-29.2%) |
| June 2024 | - | $152.82 M(-21.1%) | $550.16 M(+38.1%) |
| Mar 2024 | - | $193.58 M(>+9900.0%) | $398.36 M(-14.0%) |
| Dec 2023 | $462.96 M(+143.5%) | $962.00 K(-99.5%) | $462.96 M(-29.1%) |
| Sept 2023 | - | $202.80 M(>+9900.0%) | $652.57 M(+45.0%) |
| June 2023 | - | $1.02 M(-99.6%) | $450.00 M(+0.7%) |
| Mar 2023 | - | $258.17 M(+35.5%) | $446.90 M(+135.0%) |
| Dec 2022 | $190.15 M(-20.5%) | $190.57 M(>+9900.0%) | $190.15 M(+5004.7%) |
| Sept 2022 | - | $225.00 K(-110.9%) | $3.73 M(-84.7%) |
| June 2022 | - | -$2.07 M(-245.9%) | $24.27 M(-87.2%) |
| Mar 2022 | - | $1.42 M(-65.9%) | $190.32 M(-20.5%) |
| Dec 2021 | $239.27 M(-58.5%) | $4.15 M(-80.0%) | $239.27 M(+0.5%) |
| Sept 2021 | - | $20.77 M(-87.3%) | $238.08 M(+9.0%) |
| June 2021 | - | $163.98 M(+225.6%) | $218.47 M(-64.9%) |
| Mar 2021 | - | $50.36 M(+1602.6%) | $622.95 M(+8.1%) |
| Dec 2020 | $576.42 M(+9301.8%) | $2.96 M(+153.7%) | $576.42 M(+0.2%) |
| Sept 2020 | - | $1.17 M(-99.8%) | $575.55 M(+0.1%) |
| June 2020 | - | $568.47 M(>+9900.0%) | $575.05 M(+5670.1%) |
| Mar 2020 | - | $3.83 M(+83.6%) | $9.97 M(+62.6%) |
| Dec 2019 | $6.13 M(-98.6%) | $2.09 M(+214.5%) | $6.13 M(-97.5%) |
| Sept 2019 | - | $664.00 K(-80.4%) | $243.39 M(-4.5%) |
| June 2019 | - | $3.38 M(<-9900.0%) | $254.75 M(+0.0%) |
| Mar 2019 | - | -$2000.00(-100.0%) | $254.72 M(-40.0%) |
| Dec 2018 | $424.31 M(+623.0%) | $239.34 M(+1890.9%) | $424.31 M(+125.9%) |
| Sept 2018 | - | $12.02 M(+257.8%) | $187.86 M(-19.0%) |
| June 2018 | - | $3.36 M(-98.0%) | $231.89 M(+1.8%) |
| Mar 2018 | - | $169.58 M(+5749.6%) | $227.88 M(+288.3%) |
| Dec 2017 | $58.69 M(-39.4%) | $2.90 M(-94.8%) | $58.69 M(+4.8%) |
| Sept 2017 | - | $56.05 M(-8750.3%) | $56.01 M(>+9900.0%) |
| June 2017 | - | -$648.00 K(-269.2%) | $445.00 K(-99.5%) |
| Mar 2017 | - | $383.00 K(+77.3%) | $97.29 M(+0.4%) |
| Dec 2016 | $96.90 M | $216.00 K(-56.3%) | $96.90 M(-0.1%) |
| Sept 2016 | - | $494.00 K(-99.5%) | $96.96 M(-1.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | $96.19 M(>+9900.0%) | $98.18 M(+1182.5%) |
| Mar 2016 | - | $0.00(-100.0%) | $7.66 M(-90.2%) |
| Dec 2015 | $78.27 M(+120.7%) | $275.00 K(-83.9%) | $78.27 M(-29.1%) |
| Sept 2015 | - | $1.71 M(-69.9%) | $110.45 M(+1.0%) |
| June 2015 | - | $5.67 M(-92.0%) | $109.38 M(+3.6%) |
| Mar 2015 | - | $70.61 M(+117.5%) | $105.53 M(+197.6%) |
| Dec 2014 | $35.46 M(+51.9%) | $32.46 M(+4983.8%) | $35.46 M(+43.0%) |
| Sept 2014 | - | $638.50 K(-64.9%) | $24.80 M(+2.6%) |
| June 2014 | - | $1.82 M(+235.7%) | $24.16 M(+2.4%) |
| Mar 2014 | - | $542.50 K(-97.5%) | $23.59 M(+1.0%) |
| Dec 2013 | $23.35 M(+1248.5%) | $21.79 M(>+9900.0%) | $23.35 M(+1404.7%) |
| Sept 2013 | - | $0.00(-100.0%) | $1.55 M(-14.6%) |
| June 2013 | - | $1.25 M(+317.2%) | $1.82 M(+2.0%) |
| Mar 2013 | - | $300.00 K(>+9900.0%) | $1.78 M(+2.9%) |
| Dec 2012 | $1.73 M(-68.5%) | $0.00(-100.0%) | $1.73 M(-57.8%) |
| Sept 2012 | - | $265.00 K(-78.2%) | $4.10 M(-32.6%) |
| June 2012 | - | $1.22 M(+386.5%) | $6.08 M(+6.8%) |
| Mar 2012 | - | $250.00 K(-89.5%) | $5.69 M(+3.7%) |
| Dec 2011 | $5.49 M(+188.1%) | $2.37 M(+5.6%) | $5.49 M(+37.9%) |
| Sept 2011 | - | $2.25 M(+171.1%) | $3.98 M(+63.4%) |
| June 2011 | - | $828.00 K(+1740.0%) | $2.44 M(+53.2%) |
| Mar 2011 | - | $45.00 K(-94.8%) | $1.59 M(-16.5%) |
| Dec 2010 | $1.91 M(+9521.2%) | $863.10 K(+23.3%) | $1.91 M(+80.4%) |
| Sept 2010 | - | $700.00 K(-3967.4%) | $1.06 M(+195.1%) |
| June 2010 | - | -$18.10 K(-105.0%) | $357.80 K(-5.3%) |
| Mar 2010 | - | $360.00 K(+2489.9%) | $377.90 K(+1808.6%) |
| Dec 2009 | $19.80 K(+692.0%) | $13.90 K(+595.0%) | $19.80 K(+135.7%) |
| Sept 2009 | - | $2000.00(0.0%) | $8400.00(+31.3%) |
| June 2009 | - | $2000.00(+5.3%) | $6400.00(+45.5%) |
| Mar 2009 | - | $1900.00(-24.0%) | $4400.00(+76.0%) |
| Dec 2008 | $2500.00 | $2500.00(>+9900.0%) | $2500.00(>+9900.0%) |
| June 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2008 | - | $0.00 | $0.00 |
FAQ
- What is Iovance Biotherapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual CFF year-on-year change?
- What is Iovance Biotherapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly CFF year-on-year change?
- What is Iovance Biotherapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics TTM CFF year-on-year change?
What is Iovance Biotherapeutics annual cash flow from financing activities?
The current annual CFF of IOVA is $462.96 M
What is the all time high annual CFF for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual cash flow from financing activities is $576.42 M
What is Iovance Biotherapeutics annual CFF year-on-year change?
Over the past year, IOVA annual cash flow from financing activities has changed by +$272.81 M (+143.47%)
What is Iovance Biotherapeutics quarterly cash flow from financing activities?
The current quarterly CFF of IOVA is $41.95 M
What is the all time high quarterly CFF for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly cash flow from financing activities is $568.47 M
What is Iovance Biotherapeutics quarterly CFF year-on-year change?
Over the past year, IOVA quarterly cash flow from financing activities has changed by -$160.85 M (-79.31%)
What is Iovance Biotherapeutics TTM cash flow from financing activities?
The current TTM CFF of IOVA is $389.32 M
What is the all time high TTM CFF for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high TTM cash flow from financing activities is $652.57 M
What is Iovance Biotherapeutics TTM CFF year-on-year change?
Over the past year, IOVA TTM cash flow from financing activities has changed by -$263.25 M (-40.34%)